PASC that persist for more than 4 weeks after the acute infection are termed long COVID [12, 26, 31], with varying incidences between 10 and 70% of infected COVID-19 patients developing long COVID symptoms, depending on the study population examined, e.g., non-hospitalized, hospitalized or vaccinated patients, etc
Symptoms include: Sudden blurring or dimming of vision in one eye Loss of peripheral or central visual fields Altered color perception, particularly difficulty distinguishing between colors Presence of a relative afferent pupillary defect upon examination Recent research has identified a potential association between GLP-1 receptor agonists like tirzepatide and increased NAION incidence, though the precise mechanism remains under investigation
Advances in non-invasive neuromodulation techniques for improving cognitive function: A review
What is tirzepatide levocarnitine
Watch for signs of infection such as increased redness, swelling, pain, or discharge